New study finds advanced liver cancer patients live longer by taking anti-cancer drug sorafenib
Researchers at Mount Sinai School of Medicine in New York have found that sorafenib (Nexavar) helps patients with advanced liver cancer live about 44 percent longer compared with patients who did not receive the anti-cancer drug.